olutasidenib
Selected indexed studies
- Olutasidenib. (, 2012) [PMID:38386942]
- Olutasidenib. (, 2006) [PMID:36701506]
- Olutasidenib: First Approval. (Drugs, 2023) [PMID:36848032]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Acute myeloid leukemia management and research in 2025. (2025) pubmed
- Olutasidenib. (2012) pubmed
- Olutasidenib. (2006) pubmed
- Olutasidenib: First Approval. (2023) pubmed
- Olutasidenib: from bench to bedside. (2023) pubmed
- Olutasidenib (FT-2102) induces durable complete remissions in patients with relapsed or refractory IDH1-mutated AML. (2023) pubmed
- Olutasidenib. (2023) pubmed
- Looking Beyond the Surface: Olutasidenib and Ivosidenib for Treatment of mIDH1 Acute Myeloid Leukemia. (2024) pubmed
- Olutasidenib: a novel mutant IDH1 inhibitor for the treatment of relapsed or refractory acute myeloid leukemia. (2024) pubmed
- Olutasidenib alone or with azacitidine in IDH1-mutated acute myeloid leukaemia and myelodysplastic syndrome: phase 1 results of a phase 1/2 trial. (2023) pubmed